Natus Medical Incorporated (BABY)
Last closing price (Dec 19 4:00 EDT):
35.67 (-1.65%) ?
Natus Medical Incorporated provides neurodiagnostic and newborn care products worldwide. The company offers healthcare products used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and incubators to control the newborn’s environment; and software systems for managing and tracking disorders and diseases. The company provides newborn hearing screening product lines consisting of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners; and hearing screening supply products that are used with newborn hearing screening devices. It also offers diagnostic hearing assessment product lines, which include the Navigator Pro system, the Scout sport portable diagnostic device, and the AuDX PRO; and diagnostic hearing supply products. In addition, the company provides monitoring systems, balance and mobility products, newborn brain injury diagnostic products, thermoregulation products, and jaundice management products. Further, it offers photometers, radiometers, patient warming lamps, neonatal heatshields, pediatric scales, blanket warming cabinets, exam lights, oxygen hoods, restraining boards, and newborn circumstraints; neonatal noise attenuators, phototherapy eye masks, and x-ray shields for reproductive organs; and newborn screening data management products. The company serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was founded in 1987 and is headquartered in San Carlos, California.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
|Matt Dolan||Roth Capital Partners LLC||Buy||Oct 22, '14||32.80||36.00||Oct 22, '15||9.76%|
|Brian Weinstein||William Blair & Company, L.L.C.||Buy||Oct 07, '14||30.71||Oct 07, '15||16.15%|
|Matt Dolan||Roth Capital Partners LLC||Buy||Oct 25, '13||19.52||22.00||Oct 25, '14||69.42%|
|Jayson Bedford||Raymond James||Buy||Jul 09, '13||11.78||15.00||Jul 09, '14||107.47%|
|Matt Dolan||Roth Capital Partners LLC||Buy||Jul 09, '13||11.78||15.00||Jul 09, '14||107.47%|
|Matt Dolan||Roth Capital Partners LLC||Buy||May 20, '13||14.24||17.00||May 20, '14||71.63%|